Cargando…
ASD and ADHD Comorbidity: What Are We Talking About?
According to the scientific literature, 50 to 70% of individuals with autism spectrum disorder (ASD) also present with comorbid attention deficit hyperactivity disorder (ADHD). From a clinical perspective, this high rate of comorbidity is intriguing. What is the real significance of this dual diagno...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918663/ https://www.ncbi.nlm.nih.gov/pubmed/35295773 http://dx.doi.org/10.3389/fpsyt.2022.837424 |
_version_ | 1784668779299471360 |
---|---|
author | Hours, Camille Recasens, Christophe Baleyte, Jean-Marc |
author_facet | Hours, Camille Recasens, Christophe Baleyte, Jean-Marc |
author_sort | Hours, Camille |
collection | PubMed |
description | According to the scientific literature, 50 to 70% of individuals with autism spectrum disorder (ASD) also present with comorbid attention deficit hyperactivity disorder (ADHD). From a clinical perspective, this high rate of comorbidity is intriguing. What is the real significance of this dual diagnosis? Is ADHD in fact always present in such cases? Might the attentional impairment reported among our ASD patients actually be a distinct trait of their ASD—namely, impaired joint attention—rather than an ADHD attention deficit? Could their agitation be the consequence of this joint attention impairment or related to a physical restlessness etiologically very different from the agitation typical of ADHD? The neurobiological reality of ASD-ADHD comorbidity is a subject of debate, and amphetamine-based treatment can have paradoxical or undesirable effects in the ASD population. Consequently, does a dual diagnosis, notwithstanding its currency in the literature, prevent us from shedding sufficient light on major physiopathologic questions raised by the clinical picture of ASD? |
format | Online Article Text |
id | pubmed-8918663 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89186632022-03-15 ASD and ADHD Comorbidity: What Are We Talking About? Hours, Camille Recasens, Christophe Baleyte, Jean-Marc Front Psychiatry Psychiatry According to the scientific literature, 50 to 70% of individuals with autism spectrum disorder (ASD) also present with comorbid attention deficit hyperactivity disorder (ADHD). From a clinical perspective, this high rate of comorbidity is intriguing. What is the real significance of this dual diagnosis? Is ADHD in fact always present in such cases? Might the attentional impairment reported among our ASD patients actually be a distinct trait of their ASD—namely, impaired joint attention—rather than an ADHD attention deficit? Could their agitation be the consequence of this joint attention impairment or related to a physical restlessness etiologically very different from the agitation typical of ADHD? The neurobiological reality of ASD-ADHD comorbidity is a subject of debate, and amphetamine-based treatment can have paradoxical or undesirable effects in the ASD population. Consequently, does a dual diagnosis, notwithstanding its currency in the literature, prevent us from shedding sufficient light on major physiopathologic questions raised by the clinical picture of ASD? Frontiers Media S.A. 2022-02-28 /pmc/articles/PMC8918663/ /pubmed/35295773 http://dx.doi.org/10.3389/fpsyt.2022.837424 Text en Copyright © 2022 Hours, Recasens and Baleyte. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Psychiatry Hours, Camille Recasens, Christophe Baleyte, Jean-Marc ASD and ADHD Comorbidity: What Are We Talking About? |
title | ASD and ADHD Comorbidity: What Are We Talking About? |
title_full | ASD and ADHD Comorbidity: What Are We Talking About? |
title_fullStr | ASD and ADHD Comorbidity: What Are We Talking About? |
title_full_unstemmed | ASD and ADHD Comorbidity: What Are We Talking About? |
title_short | ASD and ADHD Comorbidity: What Are We Talking About? |
title_sort | asd and adhd comorbidity: what are we talking about? |
topic | Psychiatry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918663/ https://www.ncbi.nlm.nih.gov/pubmed/35295773 http://dx.doi.org/10.3389/fpsyt.2022.837424 |
work_keys_str_mv | AT hourscamille asdandadhdcomorbiditywhatarewetalkingabout AT recasenschristophe asdandadhdcomorbiditywhatarewetalkingabout AT baleytejeanmarc asdandadhdcomorbiditywhatarewetalkingabout |